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https://doi.org/10.1016/j.stemcr.2019.01.017SUMMARYThe relationship between diabetes and endothelial dysfunction remains unclear, particularly the associationwith pathological activation
of calpain, an intracellular cysteine protease. Here, we used human induced pluripotent stem cells-derived endothelial cells (iPSC-ECs) to
investigate the effects of diabetes on vascular health. Our results indicate that iPSC-ECs exposed to hyperglycemia had impaired
autophagy, increased mitochondria fragmentation, and was associated with increased calpain activity. In addition, hyperglycemic
iPSC-ECs had increased susceptibility to cell death when subjected to a secondary insult—simulated ischemia-reperfusion injury
(sIRI). Importantly, calpain inhibition restored autophagy and reduced mitochondrial fragmentation, concurrent with maintenance
of ATP production, normalized reactive oxygen species levels and reduced susceptibility to sIRI. Using a human iPSC model of diabetic
endotheliopathy, we demonstrated that restoration of autophagy and prevention of mitochondrial fragmentation via calpain inhibition
improves vascular integrity. Our human iPSC-EC model thus represents a valuable platform to explore biological mechanisms and new
treatments for diabetes-induced endothelial dysfunction.INTRODUCTION
Diabetes mellitus is a complex metabolic disease affecting
more than 300 million people worldwide (American Dia-
betes Association, 2014; Danaei et al., 2011). The most
common form is type 2 diabetes, characterized by a lack
of response to insulin in the peripheral tissues as well as
impaired secretion of insulin (Ako et al., 2006; American
Diabetes Association, 2014). The progression of diabetes
mellitus is closely associated with increased risk of cardio-
vascular disorders such as ischemia-reperfusion injury
(IRI), generally attributed to the adverse effects of hypergly-
cemia and oxidative stress (Gerich, 2007; Kalofoutis et al.,
2007; Martin-Timon et al., 2014).
Endothelial dysfunction constitutes an early hallmark
associated with cardiovascular disorders in diabetes. Endo-
thelial cells (ECs) have significantly impaired ability to
promote vasodilation, fibrinolysis, and anti-aggregation to
the point of developing atherosclerosis (Hadi and Suwaidi,
2007; Sena et al., 2013). Calpains, a 15-member family of
Ca2+-dependent non-lysosomal cysteine proteases, which
include the ubiquitous calpain-1 and -2 (m- andm-calpains)
have been reported to be pathologically activated inStem Cell
This is an open access artidiabetes mellitus, although the links to hyperglycemia-
induced, mitochondrial-mediated endothelial dysfunction
is not fully understood. Calpain over-activation has been
shown to lead to EC dysfunction and inflammatory re-
sponses (Goll et al., 2003; Potz et al., 2016; Stalker et al.,
2005; Suzuki et al., 2004; Vindis et al., 2005)—for instance,
calpain-1 activation promotes hyperhomocysteinemia-
induced extracellular matrix remodeling mediated by
matrix metalloproteinase 9, leading to elevated levels of
reactive oxygen species (ROS) and vascular damage (Moshal
et al., 2006; Papatheodorou and Weiss, 2007). Likewise, in-
hibition of calpain has been reported to be linked to
reduced oxidative stress and attenuation of endothelial
dysfunction in diabetes (Chen et al., 2014). On this back-
ground, perturbations in mitochondrial function have
been demonstrated to govern cell fate (Galluzzi et al.,
2012; Granville and Gottlieb, 2002; McBride et al., 2006;
Ong and Gustafsson, 2012; Parone et al., 2002). In the
setting of hyperglycemia, the dysregulation of both auto-
phagy and mitochondrial morphology have been associ-
atedwith impairment of normal cellular function and intol-
erance to injury (Fetterman et al., 2016; Jheng et al., 2012;
Jung et al., 2008; Lv et al., 2014; Yu et al., 2008). However,Reports j Vol. 12 j 597–610 j March 5, 2019 j ª 2019 The Author(s). 597
cle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
the association between calpain activation and mitochon-
drial aberration in the pathophysiology of hyperglycemic-
induced endothelial dysfunction remains to be fully
elucidated.
Ongoing studies have generated and utilized different
cellular and animal models of diabetes to study the underly-
ing mechanisms of hyperglycemic disorders. However, utili-
zation of patient-specific biological material could signifi-
cantly enhance our knowledge of the precise mechanisms
behind diabetes complications. Although a small number
of human EC lines and primary human cells have contrib-
uted significantly to the understanding of vascular biology
in the context of diabetes, the difficulty inobtainingvascular
tissues, especially in patients with specific genetic back-
grounds remains a limitation. Recent efforts have focused
on generatingpatient-specificmaterial using inducedplurip-
otent stem cells (iPSCs) that can be derived from human
somatic cells, then differentiated into desired lineages
including iPSC-derived endothelial cells (iPSC-ECs) (Sone
et al., 2007; Takahashi et al., 2007; Takahashi andYamanaka,
2006; Taura et al., 2009) or cardiomyocytes (iPSC-CMs) for
diseasemodeling (Burridgeetal., 2016;Kodoetal., 2016).Hu-
man iPSC-ECs represent a wide spectrum of usage including
cell-based therapy, diseasemodeling, and drug screening. For
example, patient-specific iPSC-ECs have been used to suc-
cessfully recapitulate in vitro theclinicalphenotypeofpulmo-
nary arterial hypertension and fibrodysplasia ossificans
progressiva (Barruet et al., 2016; Gu et al., 2017).
Here, we utilized human iPSC-ECs as a model of diabetic
endotheliopathy and sought to understand hyperglyce-
mia-induced changes to autophagy and mitochondrial
dynamics as potential pathophysiological factors leading
to endothelial dysfunction. We demonstrated that expo-
sure of iPSC-ECs to hyperglycemia led to impaired vascular
health as indicated by disrupted tube formation, increased
oxidative stress, and decreased ATP. We also showed that
hyperglycemia resulted in decreased autophagy as well
as increased mitochondrial fragmentation in iPSC-ECs.
The aforementioned effects may be attributed, in part, to
increased calpain activation, as inhibition of calpain using
MDL-28170 resulted in successful reversal. Lastly, hyper-
glycemic iPSC-ECs were more susceptible to cell death
when exposed to simulated ischemia-reperfusion injury
(sIRI) demonstrating the use of iPSC-ECs for investigating
comorbidities.RESULTS
In Vitro Monolayer Endothelial Differentiation of
Human iPSC
Human iPSCs were differentiated into ECs as described pre-
viously (Gu et al., 2017). In brief, cells were treated with598 Stem Cell Reports j Vol. 12 j 597–610 j March 5, 2019CHIR (6 mM) from day 0 to 2, followed by CHIR (2 mM)
from day 2 to 4 for mesoderm induction. From day 4 to 12
of differentiation, cells were treated with vascular endothe-
lial growth factor (VEGF), basic fibroblast growth factor
(FGF), and bone morphogenetic protein 4 (BMP4) in
EGM-2 endothelial growth medium to promote specifica-
tion to ECs. On day 12 of differentiation, iPSC-ECs were
purified by magnetic-activated cell sorting for EC surface
marker CD144 (Figure 1A). Fluorescence-activated cell sort-
inganalysis showedthat90%of the sortedCD144-positive
cellswerealsopositive foranother endothelialmarker,CD31
(Figure 1B), and the purity of iPSC-ECs generated using this
protocol was comparable with iPSC-ECs generated using an
alternativeprotocol (Patsch et al., 2015) andagainst primary
human aortic endothelial cells (HAECs) (Figure S1A). These
cells exhibited a typical cobblestone morphology of ECs
and stained positive for both CD31 and CD144 (Figures 1C
and S1B). Compared with undifferentiated iPSCs, iPSC-ECs
fromboth differentiationprotocols exhibited robust expres-
sionof endothelialmarker genesCD31,CD144, and vonWil-
lebrand Factor (vWF), although the expression of vWF in
these iPSC-ECs was lower than HAECs, confirming success-
fuldifferentiationof iPSC-ECs (Figure1D). Similar toHAECs,
differentiated iPSC-ECs also took up acetylated low-density
lipoprotein (Figure S1C) and expressed vascular cell adhesion
molecule 1 (VCAM1)when treatedwith tumornecrosis factor
alpha, a proinflammatory cytokine (Figure S1D), further
verifying these cells as bona fide iPSC-ECs.
Exposure of iPSC-ECs to Hyperglycemia Induces
Endothelial Dysfunction
As lack of neovascularization and vasculogenesis induced
by hyperglycemia often precede the progression of dia-
betic macrovascular complications, we first investigated
the effects of hyperglycemia on the endothelial differenti-
ation potential of iPSCs and differentiated iPSC-ECs. The
presence of hyperglycemia during endothelial differentia-
tion impaired the generation of CD144-positive ECs, sug-
gesting that hyperglycemia causes inhibitory effects on
the conversion of stem/progenitor cells into ECs (Fig-
ure S2A). Notwithstanding the reduced endothelial differ-
entiation potential, differentiated iPSC-ECs cultured
under hyperglycemic conditions did not appear to be
morphologically distinct compared with normoglycemic
controls (Figure S2B), although the proliferative capacity
of iPSC-ECs under hyperglycemia was significantly
reduced compared with normoglycemic iPSC-ECs (Fig-
ure S2C). These subtle differences suggest that hyperglyce-
mia predisposes ECs toward a diabetic phenotype. We
next assessed the tube formation potential of iPSC-ECs
and found that iPSC-ECs exposed to hyperglycemia had
significantly impaired tube formation ability compared
with cells in normoglycemia (Figure 2A), results which
AB C
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Figure 1. Characterization of iPSC-ECs
(A) A brief scheme of iPSC endothelial differentiation.
(B) Representative flow cytometry analysis of purified iPSC-ECs stained for both CD144 and CD31. ECs that were isolated using CD144
MicroBeads were also positive for CD31, a commonly used EC marker.
(C) iPSC-ECs demonstrated a cobblestone-like morphology and stained positive for both CD31 (red) and CD144 (green). Scale bars, 200 mm
(left panel) and 50 mm (right panel).
(D) qPCR of endothelial-markers compared with iPSCs generated using the current protocol (iPSC-EC), from an alternative protocol (iPSC-EC
NCB) and HAECs. Data are represented as means ± SEM (N = 4 independent experiments performed in triplicates, *p < 0.05 versus iPSC,
#p < 0.05 versus HAEC).were corroborated using HAECs. Hyperglycemic condi-
tions also resulted in increased oxidative stress (Figure 2B)
and reduced ATP levels (Figure 2C) compared with normo-
glycemic conditions in both iPSC-ECs and HAECs.
Measurement of autophagic levels by immunoblotting re-
vealed lower levels of both BECLIN 1 and LC3-II in iPSC-
ECs and HAECs exposed to hyperglycemia, further sup-ported by reduced presence of autophagosomes compared
with iPSC-ECs in normoglycemic condition (Figure 2D),
demonstrating an impairment in autophagy. Importantly,
hyperglycemia led to a significant increase in calpain ac-
tivity in both iPSC-ECs and HAECs (Figure 2E), which
has previously been shown to be associated with vascular
dysfunction (Miyazaki et al., 2011).Stem Cell Reports j Vol. 12 j 597–610 j March 5, 2019 599
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Figure 2. Exposure of iPSC-ECs to Hyperglycemia Leads to Endothelial Dysfunction
(A) Representative bright-field images of tube formation (angiogenic capability) of iPSC-ECs subjected to normoglycemic (NG) or hyper-
glycemic (HG) treatments. Quantitative data fromthe tube formation assay (lower panel) revealed reduced tube formationofboth iPSC-ECsand
HAECs in HG expressed as a percentage against cells in NG (control). Mean ± SEM of four independent experiments, *p < 0.05 versus NG cells.
(B and C) iPSC-ECs and HAECs exposed to HG had higher oxidative stress (B) and reduced ATP (C) compared with NG control. Data are
represented as means ± SEM of four independent experiments, *p < 0.05 versus NG cells.
(D) Representative immunoblot (top left panel) and densitometry analysis (right panel) of autophagy-related proteins BECLIN 1 and LC3-II
normalized against GAPDH in iPSC-ECs and HAECs subjected to NG or HG treatment. Data are represented as means ± SEM of four inde-
pendent experiments, *p < 0.05 versus NG cells. Cyto-ID staining of autophagosome formation in iPSC-ECs subjected to NG or HG treatment
is also shown. Scale bar, 50 mm.
(E) Measurement of calpain activity in iPSC-ECs and HAECs grown in HG versus HG, normalized against the percentage in NG-treated cells.
Data are represented as mean ± SEM of three independent experiments, *p < 0.05 versus NG cells.Calpain Inhibition Rescues Endothelial Dysfunction
in Hyperglycemic iPSC-ECs
Having shown that exposure of iPSC-ECs to hyperglycemia
led to endothelial dysfunction and was associated with600 Stem Cell Reports j Vol. 12 j 597–610 j March 5, 2019increased calpain activity, we examined whether inhibition
of calpain is beneficial for restoring endothelial health.
Treatment of iPSC-ECs and HAECs with MDL-28170, a
potent calpain I and II inhibitor (Mehdi, 1991), led to
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Figure 3. Calpain Inhibition Restores Endothelial Dysfunction in Hyperglycemic iPSC-ECs
(A) Tube formation assays were performed to assess angiogenic capacity of iPSC-ECs and HAECs treated with vehicle or MDL-28170 (MDL)
and exposed to normoglycemia (NG) or hyperglycemia (HG). Representative bright-field images of tube formation extent in iPSC-ECs in NG
or HG, with or without MDL-28170 (left panel). Data are expressed as a percentage of tube formation in NG iPSC-ECs or HAECs and represent
a means ± SEM of four independent experiments, *p < 0.05 versus NG cells, #p < 0.05 versus HG cells.
(legend continued on next page)
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decreased calpain activity (data not shown) and improved
tube formation in cells exposed to hyperglycemia (Figures
3A and S3). Likewise, whereas the presence of MDL-28170
did not modify ROS production in iPSC-ECs nor HAECs
under normoglycemic conditions, MDL-28170 successfully
reduced hyperglycemia-induced ROS production signifi-
cantly (Figure 3B). This is in line with the ATP production
whereby impairment of ATP production that occurred in
the presence of hyperglycemia was significantly reversed
by calpain inhibition (Figure 3C). Inhibition of calpain
also restored the levels of autophagy in both iPSC-ECs
and HAECs exposed to hyperglycemia marked by higher
levels of BECLIN 1 and LC3-II normalized against GAPDH
(Figure 3D) and increased formation of autophagosomes
(Figure 3E).
Hyperglycemia-Induced Mitochondrial
Fragmentation in iPSC-ECs Is Reversed by Calpain
Inhibition
Prior studies have demonstrated aberrant fragmentation of
the mitochondria under hyperglycemic conditions in a
variety of cell types (Jheng et al., 2012; Yu et al., 2008,
2017). Using MitoTracker Red staining of mitochondria,
we observed normoglycemic iPSC-ECs to have predomi-
nantly elongated mitochondria, and exposure of these
cells to hyperglycemia led to fragmentation and dispersion
of elongated mitochondria around the cytosol (Fig-
ure 4A, upper two rows). Quantitative analysis of iPSC-
ECs showed that predominantly elongated mitochondria
were significantly reduced in hyperglycemic conditions
versus normoglycemia (Figure 4B). Particle analysis of
the images using Fiji/ImageJ revealed mitochondria to
have lower aspect ratio (AR) (Figure 4C) and higher circu-
larity values (Figure 4D) under hyperglycemic conditions
indicating hyperglycemic mitochondria undergoing
fragmentation and becoming punctate. Importantly,
HAECs subjected to hyperglycemia also had reduced
number of cells with elongated mitochondria (Fig-
ure 4B), marked by lower mitochondrial AR (Figure 4C)
and higher circularity values (Figure 4D) similar to iPSC-
ECs. As we observed calpain activation in iPSC-ECs
exposed to hyperglycemia and calpain has been shown
to regulate mitochondrial dynamics previously in
other cell types, we were interested in further evalua-
tion of the association between hyperglycemia and induc-
tion of mitochondrial fission. To test whether calpain
activation following hyperglycemia is responsible for(B and C) Measurement of ROS levels (B) and ATP levels (C) in iPSC-ECs
HG. Data are represented as means ± SEM of four independent experi
(D) Measurement of autophagy levels by immunoblotting in iPSC-EC
conditions. Data are represented as means ± SEM of four independen
(E) Cyto-ID staining of autophagosomes in NG or HG iPSC-ECs treated
602 Stem Cell Reports j Vol. 12 j 597–610 j March 5, 2019induction of mitochondrial fragmentation, themitochon-
drial morphology following calpain inhibition was stud-
ied. Importantly, we observed that inhibition of calpain
using MDL-28170 prevented the fragmentation of mito-
chondria in iPSC-ECs induced by hyperglycemia with
the number of iPSC-ECs with predominantly elongated
mitochondria significantly increased (Figure 4A, lower
two rows and B), an effect corroborated using Fiji/
ImageJ-particle analysis (Figures 4C and 4D). Inhibition
of calpain in HAECs also had similar effects (Figures 4B–
4D). MDL-28170 in iPSC-ECs grown under normoglyce-
mic conditions did not significantly alter the mitochon-
drial morphology.
Gene Expression Profiling of iPSC-ECs Subjected to
Hyperglycemia
For an in-depth understanding on the effects of both hy-
perglycemia and calpain inhibition, we then performed
RNA sequencing (GEO accession number: GSE123699)
and analyzed the global expression pattern changes
among these factors—normo-/hyperglycemia and non-
treatment/MDL-28170-treated. All genes were normal-
ized by the sequencing depth, log transformed, and
variance stabilizing transformed. The principal compo-
nent analysis of all genes indicated that the genetic
background contributed the most variance (96%) in prin-
cipal component 1 (PC1), while hyperglycemia and MDL
treatments contributed to the variances of PC2 (2%)
and PC3 (1%), respectively (Figure 5A). We identified
25 differentially expressed genes (DEGs) in the hyper-
glycemia condition (Figure 5B), with 15 genes upregu-
lated in hyperglycemic group, whereas 10 genes were
downregulated in the normoglycemic group. Func-
tional enrichment analysis of the DEGs is shown in
Figure 5C, which includes several pathways related
to apoptosis such as apoptosis-induced DNA fragmenta-
tion, activation of DNA fragmentation factor, and
apoptotic execution phase, which support our findings
that hyperglycemia induces endothelial dysfunction,
possibly ultimately leading to apoptosis. In addition,
pathway analysis also revealed formation of senescence-
associated heterochromatin foci, indicating that ECs
exposed to hyperglycemia may undergo premature senes-
cence, thus affecting cellular proliferation, representing
an alternative pathway which may be explored in the
future. We also attempted to identify the genes that
had differential changes between both hyperglycemiaand HAECs treated with vehicle or MDL-28170 and exposed to NG or
ments, *p < 0.05 versus NG cells, #p < 0.05 versus HG cells.
s and HAECs treated with or without MDL-28170 under NG or HG
t experiments, *p < 0.05 versus NG cells, #p < 0.05 versus HG cells.
with or without MDL-28170.
Figure 4. Mitochondrial Morphology of iPSC-ECs Following Hyperglycemic Treatment in the Presence of MDL-28170
(A) Representative confocal images and Fiji/ImageJ outline tracings of iPSC-ECs in either normoglycemia (NG) or hyperglycemia (HG)
environments, with or without MDL-28170 (MDL), stained with MitoTracker Red (MTR) and DAPI for the nucleus. Scale bars, 10 mm.
(B) Proportion of iPSC-ECs and HAECs with elongated mitochondria in either NG or HG environment, with or without MDL-28170, data are
represented as means ± SEM of four independent experiments, *p < 0.05 versus NG cells, #p < 0.05 versus HG cells.
(C) Assessment of mitochondrial aspect ratio in iPSC-ECs and HAECs cultured in an either NG or HG environment, with or without MDL-
28170, using Fiji/ImageJ. Data are represented as means ± SEM of four independent experiments, *p < 0.05 versus NG cells, #p < 0.05
versus HG cells.
(D) Measurement of mitochondrial circularity in iPSC-ECs and HAECs in an NG or HG environment, with or without MDL-28170, using Fiji/
ImageJ. Data are represented as means ± SEM of four independent experiments, *p < 0.05 versus NG cells, #p < 0.05 versus HG cells.and MDL treatments simultaneously, but only eight
genes were detected (Figure 5D).
Hyperglycemic iPSC-ECs Have Increased
Susceptibility against sIRI that Is Reversed by Calpain
Inhibition
Diabetic patients often have increased risk of developing
additional comorbidities such as ischemia and stroke. To
investigate if diabetic iPSC-ECs were more susceptible toIRI, we subjected iPSC-ECs in both normoglycemic and hy-
perglycemic conditions to sIRI and measured cell death,
ATP production, and ROS levels. Our results demonstrated
that iPSC-ECs in hyperglycemia had significantly increased
cell death (Figure 6A), lower ATP levels (Figure 6B),
and higher oxidative stress (Figure 6C) compared with nor-
moglycemic iPSC-ECs when subjected to sIRI. In accor-
dance with earlier results, inhibition of calpain activity
via MDL-28170 successfully reduced cell death (Figure 6A),Stem Cell Reports j Vol. 12 j 597–610 j March 5, 2019 603
Figure 5. Transcriptomic Analysis of iPSC-ECs Treated with MDL-28170
(A) Principal component analysis of gene expression across two different iPSC-ECs under normo- or hyperglycemia and treated with either
vehicle or MDL-28170.
(B) Heatmap of differentially expressed genes in iPSC-ECs exposed to NG or HG, with or without MDL-28170.
(C) Pathway analysis of differentially expressed genes in hyperglycemic iPSC-ECs.
(D) Line plots of differentially expressed genes clusters between glucose and MDL treatments.improved ATP levels (Figure 6B), and lowered ROS levels
(Figure 6C) in iPSC-ECs in hyperglycemic conditions
following exposure to sIRI. To further corroborate the role
of mitochondria in determining the iPSC-ECs fate in the
hyperglycemic environment, we analyzed the relative
levels of caspase-3/7 between the different treatments in
the cells. No difference in caspase-3/7 level was detected
across the groups (Figure 6D).604 Stem Cell Reports j Vol. 12 j 597–610 j March 5, 2019DISCUSSION
In the present study, we successfully demonstrated that hu-
man iPSC-ECs can be used as a valuable disease-modeling
platform to assess endothelial dysfunction under a dia-
betic-like environment. We observed that hyperglycemia
resulted in iPSC-ECs undergoing endothelial dysfunction,
which was associated with enhanced calpain activity,
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Figure 6. Hyperglycemic iPSC-ECs Displayed Increased Susceptibility against Simulated Ischemia Reperfusion Injury that Can Be
Prevented by Calpain Inhibition
(A) Post-reoxygenation cell viability of normoglycemia (NG) or hyperglycemia (HG) iPSC-ECs, with or without MDL-28170, following
exposure to sIRI was determined by propidium iodide (PI) staining, as visualized by fluorescence microscopy. Data are represented as
means ± SEM of four independent experiments, *p < 0.05 versus NG cells, #p < 0.05 versus HG cells. Scale bars, 100 mm.
(B) ATP measurement in NG- or HG-treated iPSC-ECs following post-reoxygenation, with or without MDL-28170. Data are represented as
means ± SEM of four independent experiments, *p < 0.05 versus NG cells, #p < 0.05 versus HG cells.
(C) Measurement of ROS in NG- or HG-treated iPSC-ECs following sIRI, with and without MDL-28170. Data are represented as means ± SEM
of four independent experiments, *p < 0.05 versus NG cells, #p < 0.05 versus HG cells.
(D) Measurement of caspase-3/7 activity in NG- or HG-treated iPSC-ECs following sIRI, with and without MDL-28170. Data are represented
as means ± SEM of four independent experiments.impaired autophagy, and increased mitochondrial frag-
mentation. Blockade of calpain activity using a calpain
inhibitor, MDL-28170, successfully reversed these detri-
mental effects. Although previous studies have demon-
strated a relationship between calpain inhibition and
induction of autophagy in neurodegenerative disease
(Watchon et al., 2017), and that diabetes is associated
with calpain activation (Chen et al., 2014) and also
impaired autophagy (Fetterman et al., 2016), our study
successfully established a direct link between hyperglyce-
mia-induced autophagy impairment and perturbed mito-
chondrial dynamics with aberrant activation of calpain in
ECs. An additional strength of our study lies in the use of
human iPSC-ECs as a novel model for understanding the
pathobiology associated with hyperglycemia, as these indi-vidual-specific cells retain the genetic and epigenetic back-
grounds of the donors and can potentially be used in the
future to study the effects of patient-specific mutations
under hyperglycemia through genome editing using
isogenic lines. This is further supported by our results
demonstrating that iPSC-ECs can recapitulate the detri-
mental effects of hyperglycemia in terms of calpain activa-
tion, increased oxidative stress, and impaired autophagy
seen in primary HAECs. Interestingly, the pattern of
autophagy impairment in HAECs from a separate study
that showed only an increase in P62 without a decrease
in LC3-II (Fetterman et al., 2016), which may be due
to the difference in hyperglycemic stimulus including the
inclusion of endothelin-1 in our hyperglycemic condi-
tions, a factor known to be increased in diabetic patientsStem Cell Reports j Vol. 12 j 597–610 j March 5, 2019 605
(Schneider et al., 2002), as well as a longer treatment dura-
tion in our study. In addition, our model also revealed that
hyperglycemic iPSC-ECs had increased susceptibility
compared with control iPSC-ECs when exposed to a sec-
ondary stress (sIRI), and that calpain inhibition mitigated
the deleterious effects further expanding the use of iPSC-
ECs for studying comorbidities.
The detrimental effects of hyperglycemia encompasses
reduced autophagy (Fetterman et al., 2016; Hsu et al.,
2016), mitochondrial fragmentation (Jheng et al., 2012;
Yu et al., 2008, 2011), loss of ATP production, and increased
levels of ROS (Watanabe et al., 2014; Yu et al., 2006, 2011),
all of which can be observed in the diabetic heart, leading
to an increased susceptibility to IRI. Autophagy reduction
and mitochondrial fragmentation have also been previ-
ously linked to increased injury following IRI in the heart
(Ma et al., 2015; Ong et al., 2010). Nonetheless, we now
demonstrate this in the setting of diabetic iPSC-ECs. Cal-
pain over-activation has been observed in the settings of
streptozotocin-induced diabetes and hyperglycemic cardi-
omyocytes (Li et al., 2009). Over-activation of mitochon-
drial calpain-1 in type 1 diabetic murine heart and cultured
cardiomyocytes generates superoxide while negatively
regulating ATP5A1 protein, leading to ATP synthase disrup-
tion (Ni et al., 2016). High-fat diet and the resulting obesity
also induces over-activation of calpain-2, causing cleav-
age and degradation of autophagy-related protein 7 and
Beclin1, resulting in inhibition of autophagy (Kim et al.,
2008; Yang et al., 2010). Calpain activation following expo-
sure to pro-apoptotic stimuli also cleaves Atg5, prompting
the translocation of the truncated Atg5 from the cytosol
to the mitochondria and stimulating apoptotic cell death
via the association with the antiapoptotic molecule Bcl-
xL (Lepine et al., 2011; Shi et al., 2013; Yousefi et al.,
2006). It is worthwhile noting that our study did not differ-
entiate between the ubiquitously expressed calpain-1 and
calpain-2 isoforms. Calpain-1, found in the mitochondrial
intermembrane space acts to increase apoptosis-inducing
factor cleavage in cardiac mitochondria during ischemia-
reperfusion (Chen et al., 2011), while calpain-2, localized
to the mitochondrial matrix, participates in mitochondrial
permeability transition pore opening and inactivation of
complex I following ischemia-reperfusion (Shintani-Ishida
and Yoshida, 2015; Thompson et al., 2016), is activated
following large calcium fluxes which occurs during
apoptosis (Goll et al., 2003) andmediates b cell dysfunction
and apoptosis in type 2 diabetes (Huang et al., 2010), set-
tings which are equally relevant in our study.
The effect of calpain inhibition of mitochondrial
morphology suggests that fragmented mitochondria may
be associated with impairment of the autophagic machin-
ery to remove the damaged mitochondria, whereas the
presence of predominantly elongated mitochondria is sug-606 Stem Cell Reports j Vol. 12 j 597–610 j March 5, 2019gestive of successful clearance of damaged or dysfunctional
mitochondria. The inhibition of mitochondrial fission has
previously been demonstrated to protect against IRI in the
heart, which also aligns well with the findings of this study,
implicating a role of calpain in interfering with the balance
inmitochondrial dynamics in iPSC-ECs (Breckenridge et al.,
2003; Estaquier and Arnoult, 2007; Guo et al., 2014; Ong
et al., 2010, 2015; Xie et al., 2013). Whether the level of
calpain is further induced in the combination of hypergly-
cemia and hypoxia as in our study remains to be clarified.
Another important aspect of our study lies in establishing
the effects of calpain inhibition in iPSC-ECs subjected to
sIRI. Calpain translocation from the cytosol to the mito-
chondria occurs during ischemia, whereas reperfusion al-
lows for its activation (Hernando et al., 2010). Intuitively,
the calpain inhibitor should be administered at the onset
of reperfusion. Nonetheless, it is noteworthy to point out
that the ischemic insult is sufficient to induce mitochon-
drial fragmentation (Ong et al., 2010), thus necessitating
the presence of an inhibitor during the ischemic period
itself. Furthermore, the hyperglycemic environment in the
iPSC-ECs culture necessitates the presence of the calpain
inhibitor pre-ischemia to properly elucidate the effects of
calpain activation. Thus, in our study, the calpain inhibitor
was present pre-ischemia, throughout ischemia, as well as
during reoxygenation. Our results also suggest that the cell
death in this model of diabetic endotheliopathy may be
caspase independent and mitochondrial dependent,
althoughstudying the time responseof the cells undergoing
ischemia and reperfusion, as well as the application ofmod-
ulators of necroptosis,may elicit clearer details. Of note, the
iPSC-ECs used in this proof-of-concept study were derived
from healthy volunteers and not from diabetic patients
with a polygenic background. However, the successful reca-
pitulationof endothelial dysfunction in these healthy iPSC-
ECs when exposed to hyperglycemia will allow future work
utilizing cells derived from patients with a polygenic back-
ground formore precise diseasemodeling. Gene expression
profiling, which revealed association of senescence-related
pathways in iPSC-ECs exposed to hyperglycemia, also re-
vealed additional targets for preventing hyperglycemia-
induced endothelial dysfunction; this is supported by our
data that demonstrated reduced proliferation of iPSC-ECs
following exposure tohyperglycemia, althoughmoredefin-
itive experiments are needed to confirm the involvement
of these pathways.
In summary, we provide evidence for the association be-
tween calpain inhibition and conservation of mitochon-
drial function with regard to autophagy andmitochondrial
morphology, which ultimately leads to enhanced tolerance
to cardiac injury in the settings of diabetes. These findings
in the iPSC-ECs support a novel model for the study of dia-
betic angiopathy (micro- or macroangiopathy), whichmay
have significant implications in diabetic cardiac complica-
tions. The findings also shed further light on the mecha-
nisms underlying the benefits of calpain inhibition as a
therapeutic target in tackling cardiac disorders.EXPERIMENTAL PROCEDURES
Experimental methods are also provided in Supplemental
Information.
Cell Culture
Primary HAECs were purchased from Lonza, Cat. no. CC-2535 and
cultured in EGM-2 medium according to manufacturer’s protocol.
Generation of iPSC Lines
Somatic reprogramming was used to generate iPSC lines from two
healthy volunteers using the CytoTune-iPS 2.0 Sendai Reprogram-
ming Kit according to the manufacturer’s instructions. Two iPSC
lines were generated from each volunteer and used for experi-
ments. All procedures conformed to the UIC institutional review
board-approved protocol.
Differentiation of iPSC-ECs
Healthy iPSC-ECs (over passage 20) were split at a 1:12 ratio using
EDTA and grown for 3–4 days until they reached 75% conflu-
ence. To initiate EC differentiation, the medium was changed to
an induction medium (RPMI and B27-insulin, Thermo Fisher
Scientific) supplemented with 6 mM CHIR on day 0 and 2 mM
CHIR on day 2. For days 4–12, cells were cultured in different com-
binations of differentiation medium and EGM-2 medium from
Lonza (100% differentiation medium on day 4, 50% differentia-
tion medium and 50% EGM-2 on day 6, 25% differentiation
medium and 75% EGM-2medium on day 8, and 100% EGM-2me-
dium on day 10) with VEGF, FGF2, and BMP4 (PeproTech). At day
12 post-differentiation, cells were sorted using the human CD144
(VE-Cadherin) MicroBeads and magnetic cell sorting system (cat.
no. 130-097-857, Miltenyi Biotech), as directed by the manufac-
turer, and expanded on 0.2% gelatin-coated plates. iPSC-ECs
were then cultured in the EGM-2 medium at 37C and 5% CO2
in a humidified incubator with medium changes every other day.
Experiments described in thismanuscriptwere performed between
passages 2 and 4.
For comparison purposes, iPSC-ECs were also generated using an
alternative protocol as previously described and named iPSC-EC
NCB (Patsch et al., 2015). In brief, iPSCs were plated at a low den-
sity with Y-27632. The next day, differentiation was initiated by
the addition of 8 mMCHIR and 25 ng/mL BMP4, and the medium
was left unchanged for 3 days. On days 4 and 5, cells were cultured
in StemPro-34 medium supplemented with 200 ng/mLVEGF and
2 mM forskolin, and the medium was replaced daily. Cells were
then magnetically sorted using the human CD144 MicroBeads
on day 6.
Exposure of ECs to Hyperglycemia
iPSC-ECs (passages 2 to 4) andHAECswere seeded on 0.2% gelatin-
coated plates in EGM-2 medium for 24 h. For hyperglycemic ECs,plating medium was then exchanged into a modified EGM-2
medium containing 33 mM glucose and 10 nM endothelin-1,
and cultured for 72 h. For normoglycemic ECs, regular EGM-2me-
dium was used with the addition of mannitol as osmotic control.
MDL-28170 was used at a final concentration of 2.5 mM where
indicated.
RNA Sequencing Analysis
The sequenced reads were aligned to human genome hg38
by HISAT2 (https://ccb.jhu.edu/software/hisat2/index.shtml). We
used featureCounts (http://bioinf.wehi.edu.au/featureCounts/) to
count the raw reads with the genome annotation Ensembl
v.85. We then used DESeq2 of Bioconductor (https://bioconductor.
org/packages/release/bioc/html/DESeq2.html) to normalize the
raw counts, and generate a table of differentially express genes
(DEGs) (likelihood ratio test, p < 0.05). The general linear
model of the test: exp〖Treat〗_Glu+〖Treat〗_MDL+〖Treat〗_
Glu:〖Treat〗_MDL, and〖Treat〗_Glu:〖Treat〗_MDL is the inter-
action term of the two factors. Hierarchical clustering was imple-
mented on the DEGs. Function enrichment analyses of the clusters
of the DEGs were implemented by GeneAnswers of Bioconductor
(https://www.bioconductor.org/packages/release/bioc/html/
GeneAnswers.html).
Statistical Analysis
All values are expressed as means ± SEM. Data were analyzed
by one-way ANOVA followed by a Tukey multiple-comparison
post hoc test. Differences were considered significant at values of
p < 0.05.
ACCESSION NUMBERS
RNA sequencing data can be accessed at NCBI GEO datasets using
the accession number GSE123699.
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